Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 4Terminated 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Sarcoma 1

Conditions

Melanoma 4Sarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × IMM-101 × Clear all
NCT01539824 2024-11-25

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
12 enrolled 6 charts
Gastrointestinal

Colorectal Neoplasms

NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
2 enrolled 7 charts
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Immodulon Therapeutics Ltd

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT01559818 2023-06-22

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
10 enrolled 12 charts
Dermatologic

Melanoma

NCT01303172 2021-11-10

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
110 enrolled 14 charts
Gastrointestinal

Advanced Pancreatic Cancer

NCT01308762 2012-12-06

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Immodulon Therapeutics Ltd

Phase 1 Completed
19 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡